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Abstract Objectives: Bevacizumab has been approved by the US Food and Drug Ad-
ministration as a first-line therapy for metastatic non-small-cell lung cancer
(NSCLC), in combination with carboplatin and paclitaxel. A single Latin
American center experience was reviewed to determine the safety and efficacy
of adding bevacizumab to first-line chemotherapy in a local population.
Methods:We retrospectively identified patients with non-squamous NSCLC
treated with bevacizumab plus chemotherapy combinations as first-line chemo-
therapy between July 1, 2006, and January 30, 2011, at Sirio LibanesHospital in
Sao Paulo, Brazil. We collected data on patient characteristics, treatment
combinations, toxicities, response to treatment, and survival. Overall survival
(OS) and progression-free survival (PFS) were calculated by Kaplan–Meier
analysis, and prognostic factors were identified by the Cox regression model.
Results: A total of 56 patients were included in the final analysis (median age
62.4 years; 70% male). In 35 patients (62.5%), bevacizumab was combined
with carboplatin and paclitaxel, and in 16 patients (28.6%), it was combined
with pemetrexed and carboplatin. The response rate evaluated by the refer-
ence clinical team reached 74.5%, the median PFS was 5.3 months, and the
median OS was 14.8 months. In multivariate analysis, use of maintenance
therapy was the only predictive factor for OS (hazard ratio 6.85, 95% con-
fidence interval 2.94–15.22). No treatment-related deaths were identified, and
the overall incidence of grade 3–4 non-hematologic toxicities was 16%.
Conclusion: Our results confirm the efficacy and safety data of bevacizumab
first-line combinations for NSCLC in a Brazilian population.
Introduction
Lung cancer is the leading cause of cancer
mortality worldwide, being responsible for almost
1 million deaths per year.[1] Lung cancer death
rates are decreasing in most developed countries,
where tobacco consumption is losing its impor-
tance. In contrast, lung cancer rates andmortality
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are increasing in developing countries, including
many examples in Latin America.[2] In Brazil,
27 320 new cases of lung cancer are estimated for
the year 2012, most of which will be diagnosed at
advanced stages.[3] Non-small-cell lung cancer
(NSCLC) accounts for approximately 85% of all
lung cancers and, despite recent advances in its
treatment, this subtype is still a significant con-
tributor to the burden of lung cancer in the world.
Management of metastatic lung cancer in-
volves palliation of symptoms and prolongation
of survival with systemic treatment. Platinum-based
doublet chemotherapies are still the standard first-
line treatment for patients not harboring an acti-
vating mutation, who may benefit from first-line
target therapy such as erlotinib, geftinib, and crizo-
tinib. Addition of bevacizumab to the platinum-
based backbone has demonstrated efficacy in two
randomized phase III trials,[4,5] leading to US Food
and Drug Administration approval of this agent as
a first-line therapy for non-squamous NSCLC.[6]
In the Eastern Cooperative Oncology Group
(ECOG) 4599 trial,[7] bevacizumab added to
carboplatin and paclitaxel improved overall sur-
vival (OS) and progression-free survival (PFS)
compared with the platinum doublet alone in 878
patients with advanced non-squamous NSCLC.
The hazard ratios (HRs) for PFS and OS were
0.66 (95% confidence interval [CI] 0.57–0.77,
p< 0.001) and 0.79 (95% CI 0.67–0.92, p = 0.003)
respectively, in favor of treatment with bev-
acizumab. The median OS improved from 10.3
months to 12.3 months and response rates in-
creased from 15% to 36% with the addition of
bevacizumab. Furthermore, in a subset analysis
of patients with adenocarcinoma histology, bev-
acizumab-based therapy improved the median
OS from 10.3 months to 14.2 months.
The AVAiL (Avastin in Lung) trial[5] eval-
uated the efficacy of two doses of bevacizumab
(7.5mg/kg and 10mg/kg) or placebo added to a
3-week schedule of cisplatin and gemcitabine.
PFS (the primary endpoint of this study) was
significantly improved with bevacizumab-based
therapy versus the placebo combination (bev-
acizumab 7.5mg/kg: HR 0.75, p = 0.003; bev-
acizumab 15mg/kg: HR 0.82, p= 0.03). Although
the median OS in the AVAiL trial exceeded 13
months in both bevacizumab treatment arms, the
PFS benefit seen with bevacizumab therapy did
not translate into a statistically significant OS
benefit. Both phase III trials[4,5] reported safety
profiles for the addition of bevacizumab to che-
motherapy, with amild increase in some toxicities
related to bevacizumab, such as hypertension,
proteinuria, and bleeding events.
Additionally, a phase IV single-arm study, the
SAiL (Safety of Avastin in Lung Cancer) trial,[8]
evaluated the safety of first-line bevacizumab
together with chemotherapy in a broad patient
population. Efficacy data from this study showed
a median OS of 14.6 months (95% CI 13.8–15.3)
and a median time to tumor progression of 7.8
months (95% CI 7.5–8.1). The disease control
rate in patients with post-baseline evaluation was
89%. The incidence of clinically significant (grade
‡3) adverse events of special interest (AESIs) was
relatively low, and no new safety signals were re-
ported. Phase IV studies offer the opportunity to
mirror usual clinical practice, outside the limited
populations and restrictions of phase III trials.
In these pivotal trials of bevacizumab as first-
line therapy in metastatic NSCLC, most of the
patients included in the analysis were of White
(Caucasian) background. In the AVAiL trial,[5]
only 5% of patients included in each arm were
from Central/South America. Although the SAiL
trial[8] intended to describe a broad population,
subjects from Hispanic and African American
backgrounds represented only 4% of the total
population. Despite the approval of bevacizumab
for treatment of NSCLC in most countries in
Latin America, local experiences of efficacy and
safety are diluted in the multitude of data from
these studies. The recent publication of the Bra-
zilian experience with breast cancer showed that
outcomes in cancer treatment might differ from
those reported in developed countries, and
heterogeneity in chemotherapy use is among the
reasons that could explain this fact.[9]
Considering that lung cancer incidence and
mortality continue to increase in Brazil, and that
outcomes from use of an agent may differ between
populations because of pharmacogenomics and
particular clinical practice, analysis of regional
experience might be essential for improvement of
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local oncologic practice. Therefore, we undertook
this retrospective review to determine the efficacy
and safety of adding bevacizumab to first-line
chemotherapy for non-squamous NSCLC in a
Brazilian population.
Methods
Patients and Data Collection
We identified all patients from the Sirio Li-
banes pharmacy registry (Sao Paulo, Brazil) who
were treated for NSCLC with bevacizumab be-
tween July 2006 and January 2011. In total, 110
patients were identified, and 56 patients who met
the following criteria were included in this report:
patients were required to have non-squamous
NSCLC tumor histology; to have received at least
one cycle of first-line chemotherapy with addition
of bevacizumab; and to have good quality follow-
up data in their medical records, defined as the
presence of a clinical description of toxicities that
allowed for grading of adverse events according
to the US National Cancer Institute’s Common
Terminology Criteria for Adverse Events v3.0
(CTCAE),[10] and adequate registration of labo-
ratory and image data. Patients with more than
one primary tumor were excluded from the re-
port. Few patients with locally advanced disease
undergoing neoadjuvant treatment with bev-
acizumab were allowed; these patients were only
included in the primary response data if their
initial clinical stage was IIIB, since this stage was
included in the primary response data from large
trials. All patients who received bevacizumab
prior to a local procedure were excluded from the
analysis of PFS and OS. One patient with early-
stage NSCLC also received bevacizumab and was
included only in the safety analysis.
Patient medical records were reviewed for in-
formation regarding demographic data, tumor
characteristics, treatment types, treatment re-
sponses, and survival. Because of the long period
covered by the study and because not all radio-
logic images were available for our review—some
images being from other health institutions—the
response evaluation was based on the treating
physician’s response assessment and not on the
Response Evaluation Criteria in Solid Tumors
(RECIST). The tumor stage was determined ac-
cording to the Seventh Edition of the American
Joint Committee on Cancer staging system.[11]
All toxicity events were classified according to the
CTCAE.[10] All data on adverse events were ob-
tained for up to 28 days after the last bev-
acizumab infusion, and AESIs were reviewed
throughout the entire available follow-up.
Statistical Analysis
We created descriptive summaries for each
demographic and clinical variable. The following
variables were examined in univariate and multi-
variate analyses of OS and PFS: age, sex, perform-
ance status according to the ECOG scale, smoking
status, number of metastatic sites, type of platinum-
based chemotherapy backbone, and use of main-
tenance chemotherapy. Any systemic treatment
beyond the planned chemotherapy with platinum
was considered to be maintenance therapy, includ-
ing bevacizumab alone. The Fisher exact test was
used to assess the independence between two cate-
goric variables. Survival curves were calculated from
the start of chemotherapy, using the Kaplan–Meier
method. The two-sided log-rank test was used to test
the association between variables and OS and PFS.
In the multivariate analysis, a Cox proportional
hazard model was used to assess the simultaneous
effect of ‡2 variables on OS and PFS. To obtain the
best subset of variables in the final model, we per-
formed stepwise model selection. p-Values were de-
rived from two-sided tests, and statistical analyses
were carried out using SPSS version 17.0 software
(IBM Corporation, Somers, NY, USA).
Results
Patient Characteristics
A total of 110 patients were initially identified
from our pharmacy registry as receiving bev-
acizumab for treatment of lung cancer (figure 1).
Thirty-four patients were excluded at the outset
because they did not receive bevacizumab as first-
line treatment (n = 30) or did not actually initiate
the drug (n= 4). Subsequently, a total of 76 patients
were selected for careful medical record review.
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After exclusion of patients with insufficient follow-
up data (n= 14) and histologies not classified as
non-squamous NSCLC (n= 6), 56 patients were
included in our analysis.
Clinical characteristics of the 56 patients who
met the inclusion criteria of our study are shown
in table I. The median age of the patients was 62.4
years, and the majority were male (69.6%) and
former smokers (66.1%). Adenocarcinoma was
the most frequent histology among the patients
(71.4%). The epidermal growth factor receptor
(EGFR) mutation status was unknown for the
majority of the patients (91%). In the 51 patients
(91.1%) with stage IV disease, the most common
metastatic sites were bones (37.5%), pleura (23.2%),
the central nervous system (CNS), and lymph nodes
(21.4% each).
Treatment Data
Treatment characteristics are summarized in
table II. The median number of bevacizumab
plus chemotherapy cycles received by the patients
was six. Carboplatin and paclitaxel were asso-
ciated with bevacizumab in 62.5% of patients,
while the second choice was carboplatin and pe-
metrexed in 28.6% of patients. All patients se-
lected for this study received bevacizumab at a
dose of 15mg/kg every 3 weeks. Most patients
(57.1%) were started on a maintenance protocol,
and the median number of treatment cycles
during that phase was 7.5. Among these patients,
25% received bevacizumab and chemotherapy as
maintenance therapy (in all cases, pemetrexed
was the chemotherapy of choice) and the re-
mainder received bevacizumab as a single agent.
Efficacy Analysis
The median follow-up period for the entire
cohort was 14.3 months. For the 52 patients who
were included in the survival analysis, the median
OS was 14.7 months (95% CI 11.5–18) and the
median PFS was 5.4 months (95% CI 3.9–6.8).
Kaplan–Meier curves for OS and PFS are pre-
sented in figure 2.
The overall response rate for the 56 patients
was 74.5%, with 37 partial responses (67.2%) and
four complete responses (7.2%). One of the com-
plete responses occurred in a patient with locally
advanced disease who was referred for surgical
resection after the end of treatment, and a patho-
logically complete response was documented.
Patients who were able to reach the mainten-
ance phase received the greatest survival benefit
in our analysis. In this group, the median OS was
22.8 months (95% CI 12.4–33.1). In patients
progressing before the opportunity to initiate the
Patients preselected from the
pharmacy registry (n = 110)
Patients selected for the
chart review (n = 76)
Patients included in the
final analysis (n = 56)
Patients excluded primarily (n = 34)
•  Bevacizumab not first-line treatment (n = 30)
•  Bevacizumab not initiated (n = 4)
Patients excluded after the review (n = 20)
•  Insufficient follow-up data (n = 14)
•  Histologies not matching the inclusion criteria (n = 6)
Fig. 1. Patient selection criteria for inclusion in the study.
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maintenance phase, the median OS was remark-
ably shorter (8.1 months, 95% CI 6.8–9.4).
There was a notable trend toward longer OS in
female patients (22.76 months) than in male
patients (13.42 months), but the difference did
not reach statistical significance (p= 0.22).We also
observed a trend toward a longer median OS in
patients younger than 63 years (18.5 months) than
in older patients (12.4 months), with a p-value
of 0.15. Patients with three or more metastatic
sites had significantly shorter PFS (3.1 months,
95% CI 1.9–4.4) than patients with fewer than
three metastatic sites (6.4 months, 95%CI 4.5–8.7
months), with a p-value of 0.031.
Regarding the chemotherapy backbone asso-
ciated with bevacizumab, there was no statistical
difference in survival outcomes. Patients who re-
ceived carboplatin and paclitaxel had a median
OS of 14.5 months (95% CI 11.4–17.6) and a
median PFS of 5.5 months (95% CI 4.1–6.9),
while patients receiving carboplatin and peme-
trexed had a median OS of 15.4 months (95% CI
8.6–22.11) and a median PFS of 5.4 months (95%
CI 4.0–10.35), respectively. Performance status
and smoking history also did not influence sur-
vival outcomes in our analysis.
Table III shows the results of the multivariate
analyses of potential predictors of OS. Initiation
of maintenance therapy and female sex were both
predictors of longer OS. Although younger age
(£63 years) also tended to predict a better OS
outcome, the results were not statistically signif-
icant.
Safety Analysis
The most common clinical adverse event ob-
served was fatigue, reported in 31% of patients
and classified as grade 3 or higher in seven
Table I. Clinical and pathologic characteristics of the study popu-
lation
Characteristic Values
Age (years; median [range])a 62.4 [43–79]
Sex (no. of patients [%])
Male 39 [69.6]
Female 17 [30.4]




Smoking status (no. of patients [%])
Never smoked 11 [19.6]
Former smoker 37 [66.1]
Current smoker 8 [14.3]
Histology (no. of patients [%])
Adenocarcinoma 40 [71.4]
Non-squamous NSCLC, NOS 12 [21.4]
Large-cell 3 [5.4]
NCSLC, undifferentiated 1 [1.8]




Initial cancer stage (no. of patients [%])
III 5 [8.9]
IV 51 [91.1]




Lymph nodes 12 [21.4]
Lung 11 [19.6]
Liver 5 [8.9]
a Age at diagnosis of metastatic disease.
CNS = central nervous system; EGFR = epidermal growth factor
receptor; ECOG =Eastern Cooperative Oncology Group; NOS =not
otherwise specified; NSCLC =non-small-cell lung cancer.
Table II. Treatment characteristics and exposure in the analyzed
population
Treatment data Values
No. of chemotherapy cycles (median [range]) 6 [2–6]






No. of patients [%] 32 [57.1]
No. of cycles (median [range]) 7.5 [1–46]
Reasons to stop treatment (no. of patients [%])
Progression of disease 42 [75]
Physician’s choice 11 [19.6]
Toxicity 2 [3.6]
Patient’s choice 1 [1.8]
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patients (12.5%). Neutropenia grade 3 or higher
was observed in 13 patients (23.2%), but only five
patients (9%) developed an episode of neutro-
penic fever (table IV). A total of 24 patients had
an AESI of any grade related to bevacizumab
treatment (e.g. hypertension, bleeding, protei-
nuria, thrombotic events). The most common
AESI was hypertension, exhibited by nine patients
(16.1%), while the most common AESI of grade 3
or higher was thrombosis. We observed venous
thrombosis in three patients (5.4%) and arterial
thrombosis in two patients (3.6%). Of those two
cases of arterial thrombosis, only one was defi-
nitely related to bevacizumab, and it occurred in a
cardiac vessel, leading to discontinuation of the
treatment by the responsible physician. Although
21% of patients in our series had CNS metastases,
none of them had intracranial bleeding during
treatment with bevacizumab. Themajority of these
patients (83%) had their brain lesions treated be-
fore initiation of chemotherapy. The only patient
who developed CNS bleeding did not have CNS
metastases, and this adverse event could be attrib-
uted to bevacizumab. No treatment-related deaths
were documented in this analysis.
Discussion
In this study, we found that the addition of
bevacizumab to standard platinum-based che-
motherapy for first-line treatment of metastatic
non-squamous NSCLC in a Brazilian subset of
patients had efficacy similar to that reported in
pivotal trials of bevacizumab combinations. In
those trials, few patients from Latin America
were recruited and, to our knowledge, this is the
largest report of first-line bevacizumab in a lung
cancer population from this continent.
We observed amedian PFS of 5.4months (com-
pared with 6.2 and 6.5 months in the E4599[4] and
AVAiL[5] trials, respectively) and a median OS of
14.7 months (compared with 12.3 and >13 months
in E4599 and AVAiL, respectively). In fact, the
better comparator for our reported outcomes is the
results of the SAiL phase IV trial,[8] since they re-
flect the experience of community practice similar
to that presented here, outside the rigidity of a
phase III trial protocol. In the SAiL trial, the
median OS was 14.6 months, which is very similar
to our finding, and the time to tumor progression,
which is usually longer than the PFS, was
7.8 months.
Of note, the response rate observed in our
study was higher than those in the phase III
trials[4,5] discussed above. Of the patients in our
series, 74.5% had some response, compared with
35% and 30.4% in E4599[4] and AVAiL,[5] re-
1.0
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Fig. 2. Efficacy analysis: Kaplan–Meier curves for (a) overall sur-
vival and (b) progression-free survival.
Table III. Cox proportional hazard ratios for overall survival
Outcome HR [95% CI]
Maintenance (yes vs no) 6.8 [2.9–15.9]
Sex (female vs male) 3.4 [1.2–8.7]
Age (£63 vs >63 years) 1.5 [0.7–3.2]
CI = confidence interval; HR = hazard ratio.
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spectively. One of the hypotheses for this differ-
ence is that responses were measured by the RE-
CIST criteria in the phase III trials, whereas in
our study, tumor assessments were carried out
according to the treating physician’s clinical
practice. No specific requirements for assessment
or confirmation of responses were implemented,
which might have yielded higher responses rates
in our study. The fact that the PFS in our study
was much closer to those in the pivotal trials
suggests that some responses captured in this study
were temporary and did not impact final out-
comes. In the SAiL trial,[8] responses were like-
wise not measured using the RECIST guidelines,
and response rates were also higher than in pre-
vious reports (the response rate in the SAiL trial
was 51%). One particularly interesting finding in
our study was that one patient who was presented
as a complete response had a large lesion not in-
itially considered for surgical resection, which
developed into a cavitary lesion after four cycles of
platinum chemotherapy plus bevacizumab. Com-
plete surgical resection was possible, and no re-
sidual tumor was detected in the pathology report,
suggesting that bevacizumab can be considered as
a neoadjuvant treatment in some situations.[12]
Regarding identification of the best platinum
doublet to use in association with bevacizumab,
our study did not favor any specific regimen. The
most frequently used backbones were carboplatin
plus paclitaxel or carboplatin plus pemetrexed.
Interesting, the frequency of the association of
carboplatin and paclitaxel reported in our study
(62.5%) is very similar to the phase IV experience
reported in the ARIES (Avastin Regimens: In-
vestigation of Treatment Effects and Safety)
study,[13] in which 64% of patients received carbo-
platin plus paclitaxel as the regimen of choice. A
phase III trial[14] showed that pemetrexed added
to cisplatin provided better outcomes in non-
squamous NSCLC than gemcitabine/cisplatin.
Although bevacizumab was approved for use in
combination with carboplatin and paclitaxel,[6]
this antibody is frequently added to other che-
motherapy combinations. A promising combi-
nation is that of bevacizumab with pemetrexed
and carboplatin,[15] and new data are expected in
the near future for this combination. This retro-
spective review does not suggest a preferred reg-
imen with which to combine bevacizumab, and
future results of new phase III trials are needed to
address this question.
The factors associated with improved OS on
multivariate analysis were use of maintenance
therapy and female sex. Subgroup analysis of the
AVAiL trial also showed a better prognosis for
female patients exposed to bevacizumab, but the
E4599 study suggested the opposite, i.e. better
outcomes for male patients than for female
patients (HR for OS 0.70 [95% CI 0.57–0.87] vs
0.98 [95% CI 0.77–1.25], respectively). In the
analysis reported herein, the median age of the
sample used for OS estimation was adopted as a
marker of age division (specifically, 62.9 years).
This does notmean that we classified patients above
that age as elderly; rather, we explored differences in
outcomes comparing both percentiles of age dis-
tribution. In this analysis, we were not able to detect
any influence of age on survival outcomes.
With respect to the maintenance therapy ad-
vantage, patients who were able to initiate this
phase were nonprogressors, and it was expected
Table IV. Adverse events observed according to the National
Cancer Institute’s Common Terminology Criteria for Adverse Events
v3.0 (CTCAE)[10]
Adverse event No. of patients [%]
Grade 1/2 Grade 3/4
Fatigue 24 [42.8] 7 [12.5]
Peripheral neuropathy 16 [29.6] 5 [9.2]
Constipation 15 [28] 0
Junction pain 10 [19.2] 0
Hypertension 7 [12.5] 2 [3.6]
Bleeding
Epistaxis 6 [10.7] 0
CNS bleeding 0 1 [1.8]
Digestive bleeding 0 1 [1.8]
Thromboembolic events
Venous 0 3 [5.4]
Arterial 0 2 [3.6]
Proteinuria 1 [1.8] 0
Headache 1 [1.8] 0
Neutropenia 5 [8.9] 13 [23.2]
Neutropenic fever 0 5 [9]
Thrombocytopenia 7 [12.5] 5 [8.9]
CNS = central nervous system.
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that they would have better survival than patients
not receiving maintenance therapy, considering
that the majority of patients did not initiate main-
tenance therapy because of tumor progression.
Although our analysis did not compare use of
maintenance therapy between nonprogressor pa-
tients to better analyze the value of this treatment,
the medianOS of these patients reported here (22.7
months) suggests that this strategy can offer an
extended period of disease control for these
patients, as has previously been demonstrated by
phase III trials.[16,17] Given the limitations of our
analysis, we cannot conclude that the use of
maintenance therapy was responsible for greater
OS in our series of patients entering the mainten-
ance phase. In addition, because of the limitations
of our sample size, we combined patients receiving
bevacizumab as a single agent and those receiving
it in combination with pemetrexed as maintenance
therapy, which precludes any suggestion regarding
specific regimens.
Our safety results did not reveal any new safety
signal, and the outcomes were consistent with
those reported previously. The frequency of hy-
pertension, which was the most frequent AESI,
can be considered lower than those reported in the
literature, considering both all-grade and high-
grade events.[18] Arterial and venous thrombo-
embolic events were the most frequent high-grade
AESIs. According to meta-analyses, the overall
incidence of arterial events during bevacizumab
treatment is 2.6%[19] and that of high-grade ve-
nous thromboembolic episodes is 6.3%;[20] both
are similar to our findings. Although the in-
cidence of high-grade neutropenia in our study
was higher than that in the SAiL trial[8] (23.2% vs
6%), a meta-analysis of hematologic toxicities re-
lated to bevacizumab supports our results.[21] No
patients included in our analysis received primary
prophylaxis with myeloid growth factors, and
some of them had complete blood counts per-
formed during the second week of treatment even
if they were asymptomatic. Both facts may ex-
plain the frequency of neutropenia we observed.
There were few episodes of neutropenic fever in
our series, suggesting that use of primary prophy-
laxis with granulocyte colony-stimulating factor
might not be indicated.
Of note, no patient with CNS metastases in
our series presented with CNS bleeding during
treatment with bevacizumab. This was also shown
by the phase IV ARIES study,[13] in which 101
patients with brain lesions were treated with bev-
acizumab. Our results reinforce the observation of
the EuropeanMedicines Agency that patients with
brainmetastasis can receive bevacizumab safely.[22]
Although they present inherent limitations,
analyses of different ethnicities are important,
since they can suggest particular responses de-
pending on the genetic background. For example,
a subgroup analysis of Asian patients from the
AVAiL trial showed an OS benefit that was not
present in the main population,[23] reinforcing the
assumption that Asian ethnicity can be a positive
predictor of increased OS in NSCLC.[24] Since our
population was constituted of mixed ethnicity,
including individuals of Caucasian, Asian, and
Black origin, we cannot assume that there was any
influence of genetic constitution on our results.
Despite being the biggest reported clinical ex-
perience with bevacizumab in Brazil, this study
has several limitations. First, our results are based
on a retrospective chart review in which the pos-
sibility of underreporting adverse events was real,
although most of the clinically significant tox-
icities were expected to be captured. Second, 14
patients had insufficient follow-up data and were
excluded from the analysis, which could have led
to a selection bias favoring better results and less
toxicity. Third, as previously discussed, response
rates were not evaluated by objective criteria and
a radiologic review of the images was not per-
formed, so higher response rates than expected
could have been reported. Finally, our sample size
was not sufficient to permit conclusions about
subgroup analysis.
The data reported herein may not provide
great novelty for the management of lung cancer
worldwide, although patients from South America
have not been adequately represented in phase III
trials[4,5] and the phase IV trial[8] of bevacizumab.
However, our study does provide important data
for the oncology community in South America,
since it describes an effort by a cancer center in a
developing country to share its clinical experience
and the encouraging results obtained when ad-
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vances in oncology are incorporated into routine
clinical practice. We attempted to incorporate the
experience from other centers in Brazil into our
study in order to create a multi-institutional expe-
rience, but unfortunately this was not possible. We
believe that publications such as this one may en-
courage other centers to continue monitoring their
outcomes and to begin sharing their clinical in-
formation with the whole community as well.
Conclusion
Our results confirm efficacy and safety data
regarding the addition of bevacizumab to first-
line chemotherapy for non-squamous NSCLC
reported in major trials, and emphasize that this
may be a valid option for such patients in Latin
America.
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